Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Toll-like receptor 6 expression, sequence variants, and their association with colorectal cancer risk.

Semlali A, Almutairi M, Pathan AAK, Azzi A, Parine NR, AlAmri A, Arafah M, Aljebreen AM, Alharbi O, Almadi MA, Azzam NA, Alanazi M, Rouabhia M.

J Cancer. 2019 Jun 2;10(13):2969-2981. doi: 10.7150/jca.31011. eCollection 2019.

2.

Full-length human surfactant protein A inhibits influenza A virus infection of A549 lung epithelial cells: A recombinant form containing neck and lectin domains promotes infectivity.

Al-Qahtani AA, Murugaiah V, Bashir HA, Pathan AA, Abozaid SM, Makarov E, Nal-Rogier B, Kishore U, Al-Ahdal MN.

Immunobiology. 2019 May;224(3):408-418. doi: 10.1016/j.imbio.2019.02.006. Epub 2019 Feb 11.

3.

Direct Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria.

Riaz MS, Kaur A, Shwayat SN, Behboudi S, Kishore U, Pathan AA.

Front Microbiol. 2018 Sep 11;9:1903. doi: 10.3389/fmicb.2018.01903. eCollection 2018.

4.

Entry Inhibition and Modulation of Pro-Inflammatory Immune Response Against Influenza A Virus by a Recombinant Truncated Surfactant Protein D.

Al-Ahdal MN, Murugaiah V, Varghese PM, Abozaid SM, Saba I, Al-Qahtani AA, Pathan AA, Kouser L, Nal B, Kishore U.

Front Immunol. 2018 Jul 30;9:1586. doi: 10.3389/fimmu.2018.01586. eCollection 2018.

5.

Human Properdin Modulates Macrophage: Mycobacterium bovis BCG Interaction via Thrombospondin Repeats 4 and 5.

Al-Mozaini MA, Tsolaki AG, Abdul-Aziz M, Abozaid SM, Al-Ahdal MN, Pathan AA, Murugaiah V, Makarov EM, Kaur A, Sim RB, Kishore U, Kouser L.

Front Immunol. 2018 May 8;9:533. doi: 10.3389/fimmu.2018.00533. eCollection 2018.

6.

A Recombinant Fragment of Human Surfactant Protein D Suppresses Basophil Activation and T-Helper Type 2 and B-Cell Responses in Grass Pollen-induced Allergic Inflammation.

Qaseem AS, Singh I, Pathan AA, Layhadi JA, Parkin R, Alexandra F, Durham SR, Kishore U, Shamji MH.

Am J Respir Crit Care Med. 2017 Dec 15;196(12):1526-1534. doi: 10.1164/rccm.201701-0225OC.

7.

Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods.

Rhodes SJ, Sarfas C, Knight GM, White A, Pathan AA, McShane H, Evans TG, Fletcher H, Sharpe S, White RG.

Clin Vaccine Immunol. 2017 Mar 6;24(3). pii: e00525-16. doi: 10.1128/CVI.00525-16. Print 2017 Mar.

8.

Human C1q Induces Apoptosis in an Ovarian Cancer Cell Line via Tumor Necrosis Factor Pathway.

Kaur A, Sultan SH, Murugaiah V, Pathan AA, Alhamlan FS, Karteris E, Kishore U.

Front Immunol. 2016 Dec 21;7:599. doi: 10.3389/fimmu.2016.00599. eCollection 2016.

9.

Analysis of the Interaction between Globular Head Modules of Human C1q and Its Candidate Receptor gC1qR.

Pednekar L, Pathan AA, Paudyal B, Tsolaki AG, Kaur A, Abozaid SM, Kouser L, Khan HA, Peerschke EI, Shamji MH, Stenbeck G, Ghebrehiwet B, Kishore U.

Front Immunol. 2016 Dec 13;7:567. doi: 10.3389/fimmu.2016.00567. eCollection 2016.

10.

The hOGG1 Ser326Cys Gene Polymorphism and Breast Cancer Risk in Saudi Population.

Alanazi M, Pathan AAK, Shaik JP, Alhadheq A, Khan Z, Khan W, Al Naeem A, Parine NR.

Pathol Oncol Res. 2017 Jul;23(3):525-535. doi: 10.1007/s12253-016-0146-6. Epub 2016 Nov 7.

PMID:
27822728
11.

Complement Deposition on Nanoparticles Can Modulate Immune Responses by Macrophage, B and T Cells.

Pondman KM, Tsolaki AG, Paudyal B, Shamji MH, Switzer A, Pathan AA, Abozaid SM, Ten Haken B, Stenbeck G, Sim RB, Kishore U.

J Biomed Nanotechnol. 2016 Jan;12(1):197-216.

PMID:
27301184
12.

Lead identification for the K-Ras protein: virtual screening and combinatorial fragment-based approaches.

Pathan AA, Panthi B, Khan Z, Koppula PR, Alanazi MS, Sachchidanand, Parine NR, Chourasia M.

Onco Targets Ther. 2016 May 2;9:2575-84. doi: 10.2147/OTT.S99671. eCollection 2016. Erratum in: Onco Targets Ther. 2017 Apr 28;10 :2365.

13.

Polymorphisms in RAD51 and their relation with breast cancer in Saudi females.

Tulbah S, Alabdulkarim H, Alanazi M, Parine NR, Shaik J, Pathan AA, Al-Amri A, Khan W, Warsy A.

Onco Targets Ther. 2016 Jan 11;9:269-77. doi: 10.2147/OTT.S93343. eCollection 2016.

14.

Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status.

Rhodes SJ, Knight GM, Fielding K, Scriba TJ, Pathan AA, McShane H, Fletcher H, White RG.

Tuberculosis (Edinb). 2016 Jan;96:37-43. doi: 10.1016/j.tube.2015.10.002. Epub 2015 Nov 11.

15.

Association of DNA Repair Gene APE1 Asp148Glu Polymorphism with Breast Cancer Risk.

AlMutairi F, Pathan AA, Alanazi M, Shalaby M, Alabdulkarim HA, Alamri A, Al Naeem A, Elrobh M, Shaik JP, Khan W, Khan Z, Parine NR.

Dis Markers. 2015;2015:869512. doi: 10.1155/2015/869512. Epub 2015 Jul 16.

16.

Development and characterisation of nine polymorphic microsatellite markers for Tephrosia calophylla Bedd. (Fabaceae).

Parine NR, Lakshmi P, Kumar D, Shaik JP, Alanazi M, Pathan AA.

Saudi J Biol Sci. 2015 Mar;22(2):164-7. doi: 10.1016/j.sjbs.2014.12.009. Epub 2014 Dec 22.

17.

End stage palliative care of head and neck cancer: a case study.

Shishodia NP, Divakar DD, Al Kheraif AA, Ramakrishnaiah R, Pathan AA, Parine NR, Chandroth SV, Purushothaman B.

Asian Pac J Cancer Prev. 2015;16(3):1255-8.

18.

Association between FTO, MC4R, SLC30A8, and KCNQ1 gene variants and type 2 diabetes in Saudi population.

Bazzi MD, Nasr FA, Alanazi MS, Alamri A, Turjoman AA, Moustafa AS, Alfadda AA, Pathan AA, Parine NR.

Genet Mol Res. 2014 Dec 4;13(4):10194-203. doi: 10.4238/2014.December.4.14.

19.

Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.

Tanner R, Kakalacheva K, Miller E, Pathan AA, Chalk R, Sander CR, Scriba T, Tameris M, Hawkridge T, Mahomed H, Hussey G, Hanekom W, Checkley A, McShane H, Fletcher HA.

BMC Infect Dis. 2014 Dec 3;14:660. doi: 10.1186/s12879-014-0660-7.

20.

Molecular cloning and cDNA characterization of Camelus dromedarius putative cytochrome P450s 1A, 2C, and 3A.

Saeed HM, Alanazi MS, Shalaby MA, Alshahrani O, Ataya FS, Pathan AA, Abduljaleel ZA.

Genet Mol Res. 2014 Mar 17;13(2):2886-905. doi: 10.4238/2014.March.17.1.

21.

Crystal structure and interaction of phycocyanin with β-secretase: A putative therapy for Alzheimer's disease.

Singh NK, Hasan SS, Kumar J, Raj I, Pathan AA, Parmar A, Shakil S, Gourinath S, Madamwar D.

CNS Neurol Disord Drug Targets. 2014;13(4):691-8.

PMID:
24576002
22.

Association between PARP-1 V762A polymorphism and breast cancer susceptibility in Saudi population.

Alanazi M, Pathan AA, Abduljaleel Z, Shaik JP, Alabdulkarim HA, Semlali A, Bazzi MD, Parine NR.

PLoS One. 2013 Dec 31;8(12):e85541. doi: 10.1371/journal.pone.0085541. eCollection 2013. Erratum in: PLoS One. 2014;9(3):e92360. Arifeen, Zainul [corrected to Abduljaleel, Zainularifeen].

23.

Characterization and cross-species amplification of microsatellite markers in African Silverbill (Lonchura cantans).

Parine NR, Kumar D, Pathan AA, Elrobh MS, Khan W, Alanazi M.

Genet Mol Res. 2013 Nov 18;12(4):5634-9. doi: 10.4238/2013.November.18.12.

24.

DNA Repair Genes XRCC1, XRCC3, XPD, and OGG1 Polymorphisms among the Central Region Population of Saudi Arabia.

Alanazi M, Pathan AA, Ajaj SA, Khan W, Shaik JP, Al Tassan N, Parine NR.

Biol Res. 2013;46(2):161-7. doi: 10.4067/S0716-97602013000200007.

25.

Association of XRCC1 gene polymorphisms with breast cancer susceptibility in Saudi patients.

Al Mutairi FM, Alanazi M, Shalaby M, Alabdulkarim HA, Pathan AA, Parine NR.

Asian Pac J Cancer Prev. 2013;14(6):3809-13.

26.

Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.

Matsumiya M, Stylianou E, Griffiths K, Lang Z, Meyer J, Harris SA, Rowland R, Minassian AM, Pathan AA, Fletcher H, McShane H.

PLoS One. 2013 Jul 3;8(7):e67922. doi: 10.1371/journal.pone.0067922. Print 2013.

27.

The C allele of a synonymous SNP (rs1805414, Ala284Ala) in PARP1 is a risk factor for susceptibility to breast cancer in Saudi patients.

Alanazi M, Pathan AA, Shaik JP, Amri AA, Parine NR.

Asian Pac J Cancer Prev. 2013;14(5):3051-6.

28.

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.

Rowland R, Pathan AA, Satti I, Poulton ID, Matsumiya MM, Whittaker M, Minassian AM, O'Hara GA, Hamill M, Scott JT, Harris SA, Poyntz HC, Bateman C, Meyer J, Williams N, Gilbert SC, Lawrie AM, Hill AV, McShane H.

Hum Vaccin Immunother. 2013 Jan;9(1):50-62. doi: 10.4161/hv.22464. Epub 2012 Nov 10.

29.

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.

Pathan AA, Minassian AM, Sander CR, Rowland R, Porter DW, Poulton ID, Hill AV, Fletcher HA, McShane H.

Vaccine. 2012 Aug 17;30(38):5616-24. doi: 10.1016/j.vaccine.2012.06.084. Epub 2012 Jul 10.

30.

Induction of CD152 (CTLA-4) and LAP (TGF-β1) in human Foxp3- CD4+ CD25- T cells modulates TLR-4 induced TNF-α production.

Boswell S, Pathan AA, Pereira SP, Williams R, Behboudi S.

Immunobiology. 2013 Mar;218(3):427-34. doi: 10.1016/j.imbio.2012.05.028. Epub 2012 Jun 6.

PMID:
22749982
31.

DNA repair gene polymorphisms at XRCC1, XRCC3, XPD, and OGG1 Loci in the hyderabad population of India.

Parine NR, Pathan AA, Bobbarala V, Abduljaleel Z, Khan W, Alanazi M.

Asian Pac J Cancer Prev. 2012;13(12):6469-74.

32.

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults.

Minassian AM, Rowland R, Beveridge NE, Poulton ID, Satti I, Harris S, Poyntz H, Hamill M, Griffiths K, Sander CR, Ambrozak DR, Price DA, Hill BJ, Casazza JP, Douek DC, Koup RA, Roederer M, Winston A, Ross J, Sherrard J, Rooney G, Williams N, Lawrie AM, Fletcher HA, Pathan AA, McShane H.

BMJ Open. 2011 Nov 14;1(2):e000223. doi: 10.1136/bmjopen-2011-000223. Print 2011.

33.

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.

Griffiths KL, Pathan AA, Minassian AM, Sander CR, Beveridge NE, Hill AV, Fletcher HA, McShane H.

PLoS One. 2011;6(8):e23463. doi: 10.1371/journal.pone.0023463. Epub 2011 Aug 26.

34.

Mucuna pruriens attenuates haloperidol-induced orofacial dyskinesia in rats.

Pathan AA, Mohan M, Kasture AS, Kasture SB.

Nat Prod Res. 2011 Apr;25(8):764-71. doi: 10.1080/14786410902819087. Epub 2010 Jul 13.

PMID:
20635303
35.

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.

de Cassan SC, Pathan AA, Sander CR, Minassian A, Rowland R, Hill AV, McShane H, Fletcher HA.

Clin Vaccine Immunol. 2010 Jul;17(7):1066-73. doi: 10.1128/CVI.00047-10. Epub 2010 May 19. Erratum in: Clin Vaccine Immunol. 2011 Apr;18(4):696.

36.

Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease.

Behboudi S, Alisa A, Boswell S, Anastassiou J, Pathan AA, Williams R.

Br J Cancer. 2010 Feb 16;102(4):748-53. doi: 10.1038/sj.bjc.6605526. Epub 2010 Jan 19.

37.

Diversity of yeasts from puddles in the vicinity of midre lovénbreen glacier, arctic and bioprospecting for enzymes and fatty acids.

Pathan AA, Bhadra B, Begum Z, Shivaji S.

Curr Microbiol. 2010 Apr;60(4):307-14. doi: 10.1007/s00284-009-9543-3. Epub 2009 Dec 5.

PMID:
19967375
38.

Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis.

Smith SG, Joosten SA, Verscheure V, Pathan AA, McShane H, Ottenhoff TH, Dockrell HM, Mascart F.

PLoS One. 2009 Nov 24;4(11):e7972. doi: 10.1371/journal.pone.0007972.

39.

Paenibacillus glacialis sp. nov., isolated from the Kafni glacier of the Himalayas, India.

Kishore KH, Begum Z, Pathan AA, Shivaji S.

Int J Syst Evol Microbiol. 2010 Aug;60(Pt 8):1909-13. doi: 10.1099/ijs.0.015271-0. Epub 2009 Sep 25.

PMID:
19783613
40.

The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming.

Todryk SM, Pathan AA, Keating S, Porter DW, Berthoud T, Thompson F, Klenerman P, Hill AV.

Immunology. 2009 Sep;128(1):83-91. doi: 10.1111/j.1365-2567.2009.03073.x. Erratum in: Immunology. 2011 Apr;132(4):589.

41.

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.

Whelan KT, Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Hill AV, McShane H.

PLoS One. 2009 Jun 16;4(6):e5934. doi: 10.1371/journal.pone.0005934. Erratum in: PLoS One. 2011;6(2).doi:10.1371/annotation/ec8cc565-bf24-4898-b7ba-6e0423d5809f.

42.

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alder N, Van Wijgerden J, Hill AV, Gleeson FV, Davies RJ, Pasvol G, McShane H.

Am J Respir Crit Care Med. 2009 Apr 15;179(8):724-33. doi: 10.1164/rccm.200809-1486OC. Epub 2009 Jan 16.

43.

A comparison of IFNgamma detection methods used in tuberculosis vaccine trials.

Beveridge NE, Fletcher HA, Hughes J, Pathan AA, Scriba TJ, Minassian A, Sander CR, Whelan KT, Dockrell HM, Hill AV, Hanekom WA, McShane H.

Tuberculosis (Edinb). 2008 Nov;88(6):631-40. doi: 10.1016/j.tube.2008.06.005. Epub 2008 Sep 17.

PMID:
18801705
44.

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.

Fletcher HA, Pathan AA, Berthoud TK, Dunachie SJ, Whelan KT, Alder NC, Sander CR, Hill AV, McShane H.

Vaccine. 2008 Sep 26;26(41):5269-75. doi: 10.1016/j.vaccine.2008.07.040. Epub 2008 Aug 3.

45.

Human CD4(+) T cells recognize an epitope within alpha-fetoprotein sequence and develop into TGF-beta-producing CD4(+) T cells.

Alisa A, Boswell S, Pathan AA, Ayaru L, Williams R, Behboudi S.

J Immunol. 2008 Apr 1;180(7):5109-17.

46.

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.

Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Beveridge NE, Whelan KT, Hill AV, McShane H.

PLoS One. 2007 Oct 24;2(10):e1052. Erratum in: PLoS One. 2011;6(2).doi:10.1371/annotation/71208a01-eb32-469c-96ab-8d5e3c497fce.

47.

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.

Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE, Ambrozak DR, Precopio ML, Scheinberg P, Alder NC, Roederer M, Koup RA, Douek DC, Hill AV, McShane H.

Eur J Immunol. 2007 Nov;37(11):3089-100. Erratum in: Eur J Immunol. 2011 May;41(5):1501.

49.

Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization.

Ayaru L, Pereira SP, Alisa A, Pathan AA, Williams R, Davidson B, Burroughs AK, Meyer T, Behboudi S.

J Immunol. 2007 Feb 1;178(3):1914-22.

50.

Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.

Alisa A, Ives A, Pathan AA, Navarrete CV, Williams R, Bertoletti A, Behboudi S.

Clin Cancer Res. 2005 Sep 15;11(18):6686-94.

Supplemental Content

Loading ...
Support Center